Dave Gennert, PhD
@davegennert.bsky.social
Genetics & bio nerd | science communications & writing | Science pubs @ Insilico Medicine | recovering journal editor | uses "wicked" as an adverb | posts & opinions my own
Check out our Behind-The-Paper article talking about the intersection of #aging target research and drug dev to fill a desperate clinical need for patients with no curative therapeutic options:
communities.springernature.com/posts/ai-mee...
#IPF #drugdev #AI #genAI
communities.springernature.com/posts/ai-mee...
#IPF #drugdev #AI #genAI
AI Meets IPF: Taking an AI-Designed Drug from Target Discovery to Phase IIa
Results from the GENESIS-IPF Phase IIa trial, now published in Nature Medicine, signal the emergence of artificial intelligence-based tools as a practical, efficient paradigm for drug discovery.
communities.springernature.com
June 4, 2025 at 1:47 PM
⭐ The first clinical validation of a drug designed by AI for a disease target discovered by AI
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
June 4, 2025 at 1:47 PM
⭐ The first clinical validation of a drug designed by AI for a disease target discovered by AI
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
⭐ The first clinical trial of a targeted TNIK inhibitor in any indication
⭐ Promising evidence of safety and early efficacy, plus plasma proteomics pointing to MOA & biomarkers of response
12 months from initiation to preclinical candidate compound, avg is 3 years! Here's hoping #AI in #drugdiscovery hitting inflection point to get more & faster preclinical/clinical wins!
December 12, 2024 at 4:53 PM
12 months from initiation to preclinical candidate compound, avg is 3 years! Here's hoping #AI in #drugdiscovery hitting inflection point to get more & faster preclinical/clinical wins!
In vivo, ~one week of ISM012-042 reduces disease activity, increased HIF1a & gut barrier target genes, restored gut barrier function, decreased inflam immune cells & cytokines in colon. Both prophylactic & post-colitis induction models.
December 12, 2024 at 4:53 PM
In vivo, ~one week of ISM012-042 reduces disease activity, increased HIF1a & gut barrier target genes, restored gut barrier function, decreased inflam immune cells & cytokines in colon. Both prophylactic & post-colitis induction models.
Our Chemistry42 generative #AI platform took over & designed novel molecule w/ low solubility, high clearance, moderate permeability to keep drug high in gut & low systemically to minimize off-target HIF1a (i.e., EPO & VEGF). 67-fold enrichment in gut vs plasma, in both healthy & colitis mice.
December 12, 2024 at 4:53 PM
Our Chemistry42 generative #AI platform took over & designed novel molecule w/ low solubility, high clearance, moderate permeability to keep drug high in gut & low systemically to minimize off-target HIF1a (i.e., EPO & VEGF). 67-fold enrichment in gut vs plasma, in both healthy & colitis mice.
Our PandaOmics AI platform ID'ed PHD1/2-HIF1a signaling as high-potential #IBD target. Dysreg'ed hypoxia already known as key feature of IBD gut tissue, ISM012-042 inhibits the inhibitors to let HIF1a activate barrier-restoring gene exp. Prev PHDi (GB004) failed ph2 trial > plenty of opportunity.
December 12, 2024 at 4:53 PM
Our PandaOmics AI platform ID'ed PHD1/2-HIF1a signaling as high-potential #IBD target. Dysreg'ed hypoxia already known as key feature of IBD gut tissue, ISM012-042 inhibits the inhibitors to let HIF1a activate barrier-restoring gene exp. Prev PHDi (GB004) failed ph2 trial > plenty of opportunity.